Knowledge base · research

Semax — the ACTH(4-10) fragment in neuroprotective research

Semax is a synthetic peptide derived from the ACTH(4-10) region — a fragment of adrenocorticotropic hormone (ACTH), which acts as a signaling molecule in the body. If peptides are treated as "one of the body's languages," Semax is an artificially designed word in that language: the sequence corresponding to the ACTH(4-7) fragment was extended with a Pro-Gly-Pro tail to obtain a molecule that is more stable and devoid of classical hormonal activity. It is precisely this construction that has kept Semax a subject of preclinical research on the nervous system for decades — not as a hormone, but as a tool for probing neurotrophic pathways.

Mechanism in brief

Semax does not have a single, unambiguously identified receptor acting on a simple "lock-and-key" basis. It derives from the melanocortin family, but in the preclinical literature its neurotropic effects are described largely as independent of classical melanocortin receptor activation. The dominant mechanistic thread is an influence on the system of neurotrophic factors — above all BDNF (brain-derived neurotrophic factor) and its receptor TrkB, as well as NGF (nerve growth factor). It is the modulation of neurotrophic signaling, rather than hormonal action, that forms the axis of most research hypotheses concerning Semax.

What is under study

In the preclinical literature, Semax has been analyzed in several areas — always in model systems, not in humans in the context of a promised effect:

  • BDNF and NGF expression — in animal models and in vitro systems, the influence of Semax on the levels of neurotrophic factor transcripts and proteins, as well as the activation of the BDNF/TrkB pathway in structures such as the hippocampus, has been studied.
  • Neuroprotective processes — in animal models of cerebral ischemia, changes in markers of neuronal damage and the inflammatory response after exposure to Semax have been described; this is the study of a neuroprotection process in a model, not a declaration of therapeutic action.
  • Synaptic plasticity — in nerve tissue preparations and animal models, phenomena related to long-term potentiation (LTP) and modulation of neurotransmission have been analyzed.
  • Learning and memory processes in model systems — in behavioral tests on rodents, correlations between the administration of Semax and learning indicators in laboratory tasks have been studied, as a model for analyzing neurotrophic mechanisms.

Each of these directions is a description of what was observed in a specific model, linked to a specific pathway — not a prediction of an effect in humans.

Origin and historical context

Semax was developed in Russia, within a circle of researchers associated with the Institute of Molecular Genetics of the Russian Academy of Sciences, as a derivative of work on neuropeptide fragments of ACTH conducted from the 1980s and 1990s. The starting point was the observation that short ACTH fragments retain activity in the central nervous system while being devoid of corticotropic (hormonal) action. Adding the Pro-Gly-Pro tail was intended to increase the molecule's resistance to proteolytic enzymes and prolong its availability. This Russian lineage means that a significant portion of the primary literature on Semax comes from Eastern European laboratories, which is worth taking into account when assessing the state of knowledge.

Research specification

Semax research material is usually supplied as a lyophilisate (a powder obtained by freeze-drying), stored under refrigerated conditions in a laboratory context; after reconstitution, stability is limited and dependent on storage conditions. In preclinical studies, Semax was administered to laboratory animals via the intranasal route — the literature justifies the choice of this route by the sensitivity of peptides to degradation in the gastrointestinal tract and by studies of "nose-to-brain" transport. The quality standard for research material is a determined purity by HPLC and verification of the compound's identity (e.g., mass spectrometry). Batch parameters, including the CAS number, molecular weight, and storage conditions, are described in the relevant safety data sheet / COA.

Level of evidence

To be honest: the vast majority of data on Semax comes from in vitro studies and animal models. Data concerning humans are limited and do not allow conclusions to be drawn about an effect in a specific person. The mechanisms — from BDNF/NGF modulation to neuroprotective processes — have been described at the level of hypotheses supported by observations in model systems, not confirmed clinical effects. Interpretation also requires caution due to the concentration of sources in a single research center. The state of knowledge is best summarized by the words that appear most often in this area: further research is needed.

For research purposes only. Not for consumption by humans or animals.

Frequently asked questions

Does Semax have an identified receptor?
In the preclinical literature, Semax has not been assigned a single, unambiguously identified receptor acting on a simple lock-and-key basis. The compound derives from the melanocortin family, yet its neurotropic effects are described largely as independent of classical melanocortin receptor activation, with an emphasis on modulation of the BDNF/TrkB neurotrophic pathway. Precise identification of the binding site remains a matter of debate and requires further research.
How does Semax differ from natural ACTH in the literature?
Semax is a synthetic analog derived from the ACTH(4-10) region, in which the core corresponding to the ACTH(4-7) fragment was extended with a Pro-Gly-Pro tail. In the literature, this modification is associated with two goals: increasing the molecule's resistance to proteolysis and separating neurotropic activity from the hormonal (corticotropic) action of native ACTH.
Why is Semax studied in intranasal form?
In preclinical studies on laboratory animals, the intranasal route is chosen because peptides such as Semax are sensitive to enzymatic degradation in the gastrointestinal tract. In addition, this route is the subject of research on nose-to-brain transport. This is a description of research methodology, not an instruction for administration in humans.
Does the name 'C-Max' refer to Semax?
In some sources and colloquial usage, the term 'C-Max' appears as a synonym for Semax. In research documentation and batch identification, however, one should rely on the compound's formal name, peptide sequence, and the CAS number given in the safety data sheet in order to avoid ambiguity.
Which signaling pathways are associated with Semax in the literature?
The most frequently described direction in the literature is the influence on the system of neurotrophic factors: BDNF together with the TrkB receptor, and NGF. The phenomena of neuroprotection and synaptic plasticity studied in models are linked to these pathways. These are mechanisms observed in model systems, requiring further verification.
For research purposes only. Not for human or animal consumption. This content is scientific and informational (mechanisms and research models) and is not medical advice or usage guidance.
View product → Build a research stack → Reconstitution calculator →

Related articles

Selank — Tuftsin Analogue and the GABAergic System in Models Selank — a synthetic tuftsin analogue studied in animal models for the GABAergic pathway and neurotrophic fact Read → DSIP — an endogenous nonapeptide and research on circadian rhythm DSIP (Delta Sleep-Inducing Peptide) — an endogenous nonapeptide studied in animal models for neuroendocrine re Read → ARA-290 (Cibinetide) — the tissue-repair receptor in research ARA-290 (cibinetide) is an erythropoietin-derived peptide studied as a selective innate repair receptor agonis Read → What are peptides? Classification, mechanism and receptors Peptides are short chains of amino acids studied in vitro and in animal models. Classification by receptor, th Read →
Research newsletter
New research write-ups by email
No noise. Mechanisms, models and quality documentation — when something worthwhile appears.